Answers are grounded in this paper and cite their sources.
Biobanked tissue samples are essential for cancer research, yet pre-analytical ischemia-hypoxia during tissue handling can compromise tissue or derived models quality, limiting their value for translational research. Here, we investigated whether M101, an extracellular hemoglobin from Arenicola marina, could mitigate, indirectly by providing oxygen, handling-induced ischemia-hypoxia in cancer tissues and subsequent live 3D models. Using prostate cancer PC3 and ovarian cancer TOV-21G XG preserved ex vivo, M101 reduced the emergence of hypoxia-associated markers, including the hypoxia-inducible factor 1-alpha, and attenuated metabolic stress. In XG-derived micro-dissected 3D tumor models cultured for 8 days, M101 improved tissue morphology, reduced fragmentation, and was associated with higher proliferative activity and lower inflammatory interleukin-6 release. Together, these findings suggest that M101 helps preserve structural and functional features of biobanked tumor models during ex vivo handling. Thus, oxygen carriers could represent a bio-compatible strategy to improve the fidelity of biobanked samples and patient-derived tumor models for precision oncology applications.
No takes yet. Share an insight, caveat, or question.
Cottin et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: